- Home
- LGND
LGND
Ligand Pharmaceuticals Incorporated
as 04-02-2025 4:00pm EST
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 1992 |
| Target Price: | $145.00 | AVG Volume (30 days): | 130.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $67.72 - $129.90 | Next Earning Date: | 05-06-2025 |
| Revenue: | $167,133,000 | Revenue Growth: | 27.28% |
| Revenue Growth (this year): | 16.72% | Revenue Growth (next year): | 19.08% |
Latest Ligand Pharmaceuticals Incorporated News
LGND Breaking Stock News: Dive into LGND Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
LGND: Raising target price to $115.00
Simply Wall St.
a month ago
Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value
Argus Research
a month ago
LGND: Lowering target price to $121.00
GlobeNewswire
a month ago
Ligand to Participate in March Investor Conferences
Zacks Small Cap Research
a month ago
LGND: First Steps into Cell & Gene Therapy
MT Newswires
a month ago
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating
MT Newswires
a month ago
RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating
GuruFocus.com
a month ago
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Compare LGND vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGND Ligand Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.